Oxotremorine

Oxotremorine

Clinical data
Pregnancy category	C
Routes of administration	Oral, intravenous
ATC code	none
Legal status
Legal status	US:Experimental/not yet approved
Identifiers
IUPAC name 1-(4-Pyrrolidin-1-ylbut-2-yn-1-yl)pyrrolidin-2-one
CAS Number	70-22-4  Y
IUPHAR/BPS	302
ChemSpider	4469  N
UNII	5RY0UWH1JL
ChEMBL	ChEMBL7634  N
CompTox Dashboard (EPA)	DTXSID10220252
ECHA InfoCard	100.000.662
Chemical and physical data
Formula	C12H18N2O
Molar mass	206.289 g·mol−1
3D model (JSmol)	Interactive image
SMILES C1CCN(C1)CC#CCN2CCCC2=O
InChI InChI=InChI=1S/C12H18N2O/c15-12-6-5-11-14(12)10-4-3-9-13-7-1-2-8-13/h1-2,5-11H2 N Key:RSDOPYMFZBJHRL-UHFFFAOYSA-N N
NY  (what is this?)    (verify)

Oxotremorine is a drug that acts as a selective muscarinic acetylcholine receptor agonist. ^[1]

Oxotremorine produces ataxia, tremor and spasticity, similar to those symptoms seen in Parkinsonism, and has thus become a research tool in experimental studies aimed at determining more effective anti-Parkinsonian drugs. ^[2]

Oxotremorine also produces antipsychotic-like effects. ^[3]

See also

• Tremorine

References

1. Tang C, Castoldi AF, Costa LG (April 1993). "Effects of the muscarinic agonist oxotremorine on membrane fluidity in rat lymphocytes". Biochemistry and Molecular Biology International. 29 (6): 1047–54. PMID   8330013. INIST   4025194.
2. Craig CR, Stitzel RE, eds. (2004). Modern Pharmacology with Clinical Applications. Lippincott Williams & Wilkins. ISBN   978-0-7817-3762-3.^{[ page needed ]}
3. Maehara S, Hikichi H, Satow A, Okuda S, Ohta H (November 2008). "Antipsychotic property of a muscarinic receptor agonist in animal models for schizophrenia". Pharmacology, Biochemistry, and Behavior. 91 (1): 140–9. doi:10.1016/j.pbb.2008.06.023. PMID   18651995. S2CID   12225821. INIST   20678587.